

Robert Howard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10574708/publications.pdf>

Version: 2024-02-01

90
papers

16,562
citations

61984

43
h-index

49909

87
g-index

94
all docs

94
docs citations

94
times ranked

17654
citing authors

#	ARTICLE	IF	CITATIONS
1	Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, The, 2020, 396, 413-446.	13.7	4,658
2	Dementia prevention, intervention, and care. Lancet, The, 2017, 390, 2673-2734.	13.7	4,228
3	PERSECUTORY DELUSIONS: A REVIEW AND THEORETICAL INTEGRATION. Clinical Psychology Review, 2001, 21, 1143-1192.	11.4	744
4	Statistical methods of estimation and inference for functional MR image analysis. Magnetic Resonance in Medicine, 1996, 35, 261-277.	3.0	644
5	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. New England Journal of Medicine, 2012, 366, 893-903.	27.0	626
6	Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ: British Medical Journal, 2006, 332, 756-761.	2.3	424
7	Neuroleptic drugs in dementia: benefits and harm. Nature Reviews Neuroscience, 2006, 7, 492-500.	10.2	257
8	The Cognitive and Affective Structure of Paranoid Delusions. Archives of General Psychiatry, 2009, 66, 236.	12.3	253
9	Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. International Psychogeriatrics, 2015, 27, 7-17.	1.0	244
10	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 2019, 142, 2558-2571.	7.6	219
11	Spatial Normalization and Averaging of Diffusion Tensor MRI Data Sets. NeuroImage, 2002, 17, 592-617.	4.2	208
12	Investigation of facial recognition memory and happy and sad facial expression perception: an fMRI study. Psychiatry Research - Neuroimaging, 1998, 83, 127-138.	1.8	191
13	Isotropic resolution diffusion tensor imaging with whole brain acquisition in a clinically acceptable time. Human Brain Mapping, 2002, 15, 216-230.	3.6	172
14	An educational intervention can prevent delirium on acute medical wards. Age and Ageing, 2005, 34, 152-156.	1.6	167
15	A Randomized, Controlled Trial With 6-Month Follow-Up of Repetitive Transcranial Magnetic Stimulation and Electroconvulsive Therapy for Severe Depression. American Journal of Psychiatry, 2007, 164, 73-81.	7.2	157
16	Tract-specific anisotropy measurements in diffusion tensor imaging. Psychiatry Research - Neuroimaging, 2006, 146, 73-82.	1.8	148
17	Phenomenology, demography and diagnosis in late paraphrenia. Psychological Medicine, 1994, 24, 397-410.	4.5	145
18	The Effect of an Online Cognitive Training Package in Healthy Older Adults: An Online Randomized Controlled Trial. Journal of the American Medical Directors Association, 2015, 16, 990-997.	2.5	143

#	ARTICLE	IF	CITATIONS
19	Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 725-733.	2.6	140
20	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002660.	8.4	131
21	Determining the minimum clinically important differences for outcomes in the DOMINO trial. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 812-817.	2.7	126
22	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , The, 2015, 14, 1171-1181.	10.2	124
23	The cerebellum and decision making under uncertainty. <i>Cognitive Brain Research</i> , 2004, 20, 46-53.	3.0	118
24	In vivo visualization of age-related differences in the locus coeruleus. <i>Neurobiology of Aging</i> , 2019, 74, 101-111.	3.1	117
25	A Comparative Study of 470 Cases of Early-Onset and Late-Onset Schizophrenia. <i>British Journal of Psychiatry</i> , 1993, 163, 352-357.	2.8	113
26	The relationship between anxiety disorders and age. , 1998, 13, 79-99.		109
27	Guidelines for the management of agitation in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 714-717.	2.7	101
28	Questions EMERGE as Biogen claims Aducanumab turnaround. <i>Nature Reviews Neurology</i> , 2020, 16, 63-64.	10.1	98
29	Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2020, 143, 2895-2903.	7.6	84
30	Do subjective memory complaints precede dementia? A three-year follow-up of patients with supposed "benign senescent forgetfulness". <i>International Journal of Geriatric Psychiatry</i> , 1992, 7, 481-486.	2.7	79
31	Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences. <i>Nature Communications</i> , 2020, 11, 1712.	12.8	74
32	Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial). <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 726-733.	1.2	73
33	Neuropsychological Impairment in Stroke, Carotid Stenosis, and Peripheral Vascular Disease. <i>Stroke</i> , 1999, 30, 2167-2173.	2.0	69
34	Can we learn lessons from the FDA's approval of aducanumab?. <i>Nature Reviews Neurology</i> , 2021, 17, 715-722.	10.1	66
35	The need to show minimum clinically important differences in Alzheimer's disease trials. <i>Lancet Psychiatry</i> , the, 2021, 8, 1013-1016.	7.4	60
36	The incidence of very late-onset psychotic disorders: a systematic review and meta-analysis, 1960-2016. <i>Psychological Medicine</i> , 2018, 48, 1775-1786.	4.5	58

#	ARTICLE	IF	CITATIONS
37	Antipsychotic prescribing to people with dementia during COVID-19. <i>Lancet Neurology</i> , The, 2020, 19, 892.	10.2	56
38	Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 140-145.	2.7	55
39	Misunderstanding the Intentions of Others: An Exploratory Study of the Cognitive Etiology of Persecutory Delusions in Very Late-Onset Schizophrenia-Like Psychosis. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 410-418.	1.2	55
40	Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. <i>Lancet Psychiatry</i> , the, 2018, 5, 553-563.	7.4	53
41	White matter signal hyperintensities in the brains of patients with late paraphrenia and the normal, community-living elderly. <i>Biological Psychiatry</i> , 1995, 38, 86-91.	1.3	50
42	Reasoning under uncertainty: heuristic judgments in patients with persecutory delusions or depression. <i>Psychological Medicine</i> , 2006, 36, 1109-1118.	4.5	49
43	Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the Tj ETQq1 1 0.784314 rgBT /Overl...	2.7	48
44	NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. <i>BMJ Open</i> , 2014, 4, e006364.	1.9	47
45	Permeable walls, floors, ceilings and doors. Partition delusions in late paraphrenia. <i>International Journal of Geriatric Psychiatry</i> , 1992, 7, 719-724.	2.7	46
46	Depression in older people with mild stroke, carotid stenosis and peripheral vascular disease: a comparison with healthy controls. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 175-183.	2.7	42
47	Which factors affect treatment response in late paraphrenia?. <i>International Journal of Geriatric Psychiatry</i> , 1992, 7, 667-672.	2.7	40
48	Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: A multi-centre randomised controlled trial. <i>Journal of Affective Disorders</i> , 2008, 109, 273-285.	4.1	40
49	Non-pharmacological interventions in the prevention of delirium. <i>Age and Ageing</i> , 2009, 38, 374-379.	1.6	39
50	Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial. <i>Trials</i> , 2013, 14, 349.	1.6	38
51	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2021, 398, 1487-1497.	13.7	31
52	Demographic and clinical features of patients attending a memory clinic. <i>International Journal of Geriatric Psychiatry</i> , 1993, 8, 497-501.	2.7	30
53	Trazodone use and risk of dementia: A population-based cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002728.	8.4	29
54	Psychiatric disorders and risk of subsequent dementia: Systematic review and meta-analysis of longitudinal studies. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.7	29

#	ARTICLE	IF	CITATIONS
55	Seeing Visual Hallucinations with Functional Magnetic Resonance Imaging. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997, 8, 73-77.	1.5	28
56	Should the diagnosis of late paraphrenia be abandoned?. <i>Psychological Medicine</i> , 1992, 22, 11-14.	4.5	26
57	Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1080-1090.	1.9	24
58	Apolipoprotein e genotype and late paraphrenia. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 147-150.	2.7	22
59	The FEAR: a rapid screening instrument for generalized anxiety in elderly primary care attenders. , 1999, 14, 60-68.		22
60	Prescription of antipsychotics in people with dementia. <i>British Journal of Psychiatry</i> , 2014, 205, 4-5.	2.8	22
61	The Incidence of Nonaffective, Nonorganic Psychotic Disorders in Older People: A Population-based Cohort Study of 3 Million People in Sweden. <i>Schizophrenia Bulletin</i> , 2019, 45, 1152-1160.	4.3	22
62	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. <i>BMJ Open</i> , 2016, 6, e011584.	1.9	21
63	Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 194-200.	2.5	21
64	Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 396-404.	2.7	18
65	Service and treatment engagement of people with very late-onset schizophrenia-like psychosis. <i>BJPsych Bulletin</i> , 2016, 40, 185-186.	1.1	17
66	Diagnosed depression and sociodemographic factors as predictors of mortality in patients with dementia. <i>British Journal of Psychiatry</i> , 2018, 213, 471-476.	2.8	15
67	Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [¹⁸ F]fallypride positron emission tomography. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 1001-1009.	2.7	13
68	Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. <i>British Journal of Psychiatry</i> , 2016, 209, 378-384.	2.8	13
69	Late paraphrenia revisited. <i>British Journal of Psychiatry</i> , 1997, 171, 406-408.	2.8	11
70	Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 708-716.	1.2	10
71	Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. <i>Journal of the American Heart Association</i> , 2019, 8, e011938.	3.7	10
72	Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-62.	0.7	10

#	ARTICLE	IF	CITATIONS
73	Prevention, diagnosis and treatment of delirium: staff educational approaches. Expert Review of Neurotherapeutics, 2006, 6, 741-751.	2.8	9
74	The Relationship Between Anxiety and Incident Agitation in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 1119-1127.	2.6	9
75	FDG-PET assessment of the locus coeruleus in Alzheimer's disease. NeuroImage Reports, 2021, 1, 100002.	1.0	9
76	Male gender influences response to an educational package for delirium prevention among older people: a stratified analysis. International Journal of Geriatric Psychiatry, 2006, 21, 493-497.	2.7	8
77	Late-onset schizophrenia and very late-onset schizophrenia-like psychosis. Reviews in Clinical Gerontology, 2001, 11, 337-352.	0.5	7
78	Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies. Health Technology Assessment, 2021, 25, 1-202.	2.8	7
79	Differences in Late- and Early-Onset Schizophrenia. American Journal of Psychiatry, 1993, 150, 846-846.	7.2	6
80	Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12157.	3.7	6
81	Sedative Load in Community-Dwelling Older Adults with Mild-to-Moderate Alzheimer's Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls. Drugs and Aging, 2020, 37, 829-837.	2.7	5
82	Adapting and Optimizing Problem Adaptation Therapy (PATH) for People With Mild-Moderate Dementia and Depression. American Journal of Geriatric Psychiatry, 2021, 29, 192-203.	1.2	5
83	Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT. Health Technology Assessment, 2018, 22, 1-62.	2.8	5
84	Drug Treatment of Schizophrenia and Delusional Disorder in Late Life. International Psychogeriatrics, 1996, 8, 597-608.	1.0	3
85	Schizophrenia and delusional disorder in late life. Reviews in Clinical Gerontology, 1996, 6, 63-73.	0.5	2
86	The importance of high quality trials of cognitive interventions in Alzheimer's disease. International Psychogeriatrics, 2016, 28, 705-706.	1.0	2
87	Suicidal ideation in dementia: associations with neuropsychiatric symptoms and subtype diagnosis. International Psychogeriatrics, 2022, 34, 399-406.	1.0	2
88	Raymond Levy and paranoid states of late life. International Journal of Geriatric Psychiatry, 1996, 11, 355-361.	2.7	1
89	LETTER TO THE EDITOR. DEMOGRAPHIC AND PHENOMENOLOGICAL FEATURES OF A SPANISH POPULATION OF PATIENTS WITH LATE PARAPHRENIA. International Journal of Geriatric Psychiatry, 1996, 11, 745-747.	2.7	1
90	Cognitive impairment in late life schizophrenia: a suitable case for treatment?. , 1998, 13, 400-404.		1